Organogenesis - Class A opened at $1.05, in line with its previous close of $1.05. In the last trading session, the stock traded between $0.95 and $1.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Organogenesis - Class A is now worth
$ 8.72
Resulting in a loss of
$ 91.28 (91.28%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.09 (-8.29%)
Day High
$1.06
Day Low
$0.95
Day Open
$1.05
Prev Close
$1.05
Volume
11,00,733
1W Return
10.69%
1M Return
-21.39%
3M Return
-49.18%
6M Return
-58.67%
1Y Return
-85.18%
Fundamentals
Market Cap ($ Mn)
125
PE Ratio
-
PB Ratio
1.51
PEG Ratio
-
ROE
14.31%
ROCE
10.46%
EPS (TTM)
$-0.25
Investment Returns
1 Week
10.69%
1 Month
-21.39%
3 Months
-49.18%
6 Months
-58.67%
9 Months
-74.39%
Financials
Quarterly
All values in $ Mn
100.8
Jun 25
150.5
Sep 25
225.1
Dec 25
36.3
Mar 26
42.8
Jun 26
45.5
Sep 26
Updates
6Nov
Organogenesis Holdings FY26 Results: Sales guidance narrows to $179.4M-$200M
Organogenesis Holdings narrowed FY2026 sales guidance to $179.4 million-$200.0 million. Previous guidance range was $179.0 million-$215.0 million. Revised upper limit of $200.0 million is below the $196.05 million analyst estimate.
7 days ago
13Oct
Organogenesis Holdings reports positive PREPARE1 trial results for DFU treatment
Organogenesis Holdings announced publication of PREPARE1 trial results in Journal of Wound Care. Study showed statistically significant wound closure improvements at 12 weeks. PuraPly AM plus standard of care outperformed standard of care alone. Results support use in hard-to-heal diabetic foot ulcer population.
1mo ago
7Aug
Truist Securities lowers Organogenesis price target to $2 on Hold
Truist Securities analyst Ravi Misra maintains a Hold rating on Organogenesis Holdings (NASDAQ: ORGO) but cuts the price target from $3 to $2. The revision reflects a more conservative valuation, reducing the implied upside for investors. The change underscores cautious sentiment toward the biotech firm's near-term prospects.
3mo ago
9Jul
Organogenesis Holdings Inc. to report Q2 FY26 results on August 6
Organogenesis Holdings Inc. will release its Q2 FY26 financial results on August 6, 2026, followed by a conference call at 5:00 p.m. ET. The webcast will be archived for one year.
4mo ago
7Jul
FDA accepts Organogenesis BLA for ReNu knee OA therapy
Organogenesis Holdings Inc. announced that the FDA has accepted its BLA for ReNu, a therapy for symptomatic knee osteoarthritis. The FDA set a PDUFA target action date of April 24, 2027. The therapy, studied in over 1,300 patients, aims to offer a non-surgical option for knee OA pain.
